COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
18/10/2018
- Five oral abstracts to be presented at annual meeting and subspecialty days – -24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- [...]
T2 Biosystems Announces 2018 Third Quarter Financial and Operational Results Release and Conference Call Date
18/10/2018
LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq: TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare [...]
Agios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018
18/10/2018
CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company [...]
Notice of Results
18/10/2018
Shire to announce third quarter 2018 results Dublin, Ireland – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce third quarter 2018 earnings on Thursday November 1, 2018. Results press release will be [...]
Homology Medicines Presents Long-Term Efficacy Data of a Single Dose of Gene Therapy Development Candidate for Treatment of Phenylketonuria
18/10/2018
BEDFORD, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today long-term efficacy data of a single dose of its lead gene therapy candidate for the [...]
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
18/10/2018
NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions
18/10/2018
The Company will also present at the BioEurope, Annual Vascular Interventional Advances and Cell and Gene Therapy Manufacturing conferences, all held in November HAIFA, Israel, Oct. 18, 2018 (GLOBE NEWSWIRE) -- [...]
Avivagen Announces Distribution Agreement for Vivamune™ in Vietnam
18/10/2018
OTTAWA, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has entered into a distribution agreement for Vivamune™ Health Chews in the Vietnamese market with Viphavet [...]
Enzymatica AB: Notice of Extraordinary General Meeting in Enzymatica AB (publ)
18/10/2018
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Press release Lund on October 18, 2018 Notice of [...]
Sales of Olainfarm Group in Nine Month Increase By 4%.
18/10/2018
Consolidated Results of September and 9 months of 2018 Preliminary consolidated Olainfarm Group sales in September 2018 reached 9.5 million euros, which represents a slight decrease of 1% compared to sales of September [...]
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
18/10/2018
LONDON, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with [...]
Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million
18/10/2018
Press release October 18, 2018 The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million The Board of Directors of Enzymatica AB (publ) has decided to carry out a rights issue of a maximum of [...]
Rule 2.9 Announcement
18/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 18 October 2018 [...]
Enzymatica AB: Enzymatica signs agreement for the Japanese market
18/10/2018
Press release October 18, 2018 Enzymatica signs agreement for the Japanese market Enzymatica has entered into an agreement with a large Japanese pharmaceutical company regarding registration, marketing, distribution and [...]
Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion
18/10/2018
Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. ( [...]
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18/10/2018
Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177 Lu-PSMA-617 , a potential first-in-class radioligand therapy in Phase III [...]
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
18/10/2018
Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113% cc) driven by continued [...]
Novartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance future
18/10/2018
Hausse du chiffre d'affaires net de 6% (tcc[1], +3% USD), stimulée principalement par: Cosentyx , qui a progressé à USD 750 millions (+37% tcc) grâce à une forte croissance en volume dans toutes ses indications Entresto [...]
Aclaris Announces Pricing of Public Offering of Common Stock
18/10/2018
WAYNE, Pa., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to [...]

Pages